KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to -$2.5 million.

  • West Pharmaceutical Services' Gains from Investment Securities changed N/A to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.6 million, marking a year-over-year decrease of 4750.5%. This contributed to the annual value of $71.4 million for FY2024, which is 2136.56% down from last year.
  • West Pharmaceutical Services' Gains from Investment Securities amounted to -$2.5 million in Q3 2025.
  • West Pharmaceutical Services' Gains from Investment Securities' 5-year high stood at $174.1 million during Q3 2021, with a 5-year trough of -$16.7 million in Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $29.5 million, with a median of $11.5 million in 2023.
  • Within the past 5 years, the most significant YoY rise in West Pharmaceutical Services' Gains from Investment Securities was 926315.79% (2021), while the steepest drop was 17260.87% (2021).
  • West Pharmaceutical Services' Gains from Investment Securities (Quarter) stood at -$16.7 million in 2021, then surged by 640.72% to $90.3 million in 2022, then fell by 14.4% to $77.3 million in 2023, then tumbled by 37.65% to $48.2 million in 2024, then crashed by 105.19% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, $4.0 million for Q2 2025, and $2.9 million during Q1 2025.